PAVmed (NASDAQ:PAVM) Cut to “Hold” at Zacks Research

Zacks Research downgraded shares of PAVmed (NASDAQ:PAVM) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on PAVM. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a report on Wednesday, October 8th. Ascendiant Capital Markets raised their target price on PAVmed from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.00.

PAVmed Trading Up 8.7%

Shares of PAVmed stock opened at $0.36 on Monday. The firm has a market capitalization of $10.76 million, a PE ratio of -0.64 and a beta of 1.10. PAVmed has a 12 month low of $0.30 and a 12 month high of $1.25. The business’s 50-day moving average price is $0.42 and its 200-day moving average price is $0.51.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC lifted its holdings in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the period. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. 19.93% of the stock is owned by institutional investors.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.